Introduction

The AI in oncology market is drawing growing attention from healthcare providers, technology vendors and research institutions because it responds to two pressing challenges at once: the rising global burden of cancer and the shortage of healthcare professionals. According to Polaris Market Research, the global AI in oncology market was valued at USD 6.51 billion in 2025 and is expected to grow at a CAGR of 27.1% from 2026 to 2034. The 2026 estimate stands at USD 8.26 billion, with the 2034 projection reaching USD 56.44 billion.

This article focuses on the technology layer behind that expansion: the software, imaging and screening capabilities that are changing how cancer is detected, diagnosed and managed.

Software Solutions Anchor the Technology Mix

By component, the market is divided into software solutions, hardware and services. Software solutions led in 2025 with a 71.5% share. That leadership is fueled by the growing use of AI-powered software for cancer diagnosis, treatment planning, medical imaging analysis and clinical decision support. The report also links the segment’s strength to the development of optimized oncological products and the better outcomes associated with their use.

Vendors are actively working to make these tools accessible to a broader population, and entrepreneurial start-ups are contributing innovative solutions for cancer treatment and prediction. One example is MedCognetics, which obtained FDA approval in December 2022 for QmTRIAGE, an AI-enabled platform designed for breast cancer screening. The platform is anticipated to reduce both the cost and time associated with imaging while improving overall outcomes.

From Manual Review to Intelligent Workflows

Traditional oncology relies on manual image analysis and clinical evaluation, which can lengthen diagnosis timelines and introduce variability in interpretation. AI-powered oncology applies AI-based imaging analysis and automated data processing to enable faster cancer detection, and it improves accuracy by identifying subtle patterns in imaging, pathology and molecular data.

For hospital and laboratory decision makers, workflow efficiency is as relevant as accuracy. Where conventional care requires significant manual review, documentation and coordination among healthcare teams, AI automates data analysis, reporting and decision support to improve clinical workflows.

The shift is visible in specific products as well. In March 2023, Qritive introduced QAi Prostate, an AI-powered tool for diagnosing prostate cancer. It supports accurate identification of prostatic adenocarcinoma regions and the classification of benign and malignant tumors in biopsy samples.

Enabling Precision Oncology

Precision medicine and early cancer detection capabilities are identified as key growth drivers. Precision oncology depends on patient-specific genomic, clinical and real-time data analysis, which contrasts with traditional treatment decisions that are mainly based on standard guidelines and clinical factors.

Looking ahead, the report points to rising integration of AI technologies in precision oncology and personalized cancer treatment. Advancements in deep learning, machine learning and genomic analytics are enhancing cancer detection, diagnosis and therapy selection. Adoption of AI-powered imaging systems and cloud-based oncology platforms is also growing, which is expected to improve accessibility, collaboration and clinical decision-making.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

https://www.polarismarketresearch.com/industry-analysis/ai-in-oncology-market 

Demand Drivers and Constraints

The escalating prevalence of cancer remains the central driver. According to the WHO, cancer is the primary cause of death across the globe, contributing to nearly one in six deaths, or 10 million people. Lung cancer accounted for 2.2 million cases and 1.8 million deaths in 2020. Combined with shortages of healthcare professionals, this is pushing adoption of AI to deliver efficient and accurate diagnoses and treatments. Investment in research and development by public and private organizations is also expected to contribute significantly.

Challenges remain. The market faces stringent regulations linked to AI-enabled products and concerns about high costs and the potential displacement of the human workforce. Data privacy and security concerns also feature among the restraints identified in the report.

Pandemic Impact and Integration Trends

The report notes that the COVID-19 pandemic had a positive impact on the market. Movement restrictions, especially in hospitals and homecare settings, created challenges for diagnosis, care and treatment, which increased the need for products that offer solutions in remote locations, particularly at an early stage. The shortage of medical professionals further amplified the use of AI to deliver improved results for patients.

Technological advancements and the integration of AI in applications such as classification, detection, characterization and monitoring are also supporting growth, along with government and private investment aimed at improving diagnostic and therapeutic capabilities.

Regional Landscape

North America dominated the market with a 42.8% revenue share in 2025, supported by well-established digital healthcare infrastructure, favorable reimbursement policies and a strong presence of AI technology and oncology solution providers. Asia Pacific is projected to register the highest CAGR, at 32.4%, driven by rising digitalization of diagnostic laboratories and hospitals, increasing cancer prevalence and expanding investments in AI-enabled healthcare.

Key Players

Major companies operating in the global market include Azra AI, IBM, Siemens Healthcare GmbH, Intel Corporation, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., ConcertAI, Median Technologies and PathAI.

Conclusion

Software is the foundation of the AI in oncology market, and its role in imaging, screening and decision support is already visible in regulatory approvals and new product launches. For stakeholders evaluating opportunities, the combination of rising cancer prevalence, healthcare workforce shortages and growing investment points to sustained momentum, while regulation, cost and data security remain factors to monitor.

More Trending Latest Reports By Polaris Market Research:

Autonomous Port Operations Systems Market

Insecticides Market

Remote Monitoring and Control Market

Biodiversity Credit Market

U.S. Rockets and Missiles Market

Psoriasis Drug Market

Fuel Cell Market

Automotive Wiring Harness Market

Dc Distribution Network Market